Dogwood Therapeutics Enters Into Securities Subscription Agreement For $5 Investment From CK Life Sciences’ Subsidiary

- Largest Shareholder Increases Position as Dogwood Advances Halneuron® Toward Topline Phase 2b Data Readout in November 2026 -

- Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory Activities -

ATLANTA, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that the Company has entered into a securities subscription agreement (the "Subscription Agreement") for a $5 million investment from the Company’s largest shareholder, a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. ("CKLS"). The investment comes as Dogwood continues to advance its ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathic Pain ("CINP") trial toward topline data readout in November 2026. Proceeds from this investment will enable the advancement of Phase 3 preparatory activities and extend operational runway through March 2027.

Pursuant to the terms of the Subscription Agreement, Dogwood will issue an aggregate of 4,098,360 shares of Common Stock at a price of $1.22 per share. The private placement is being priced at-the-market under the rules of The Nasdaq Stock Market. No warrants or other derivative securities are included in the transaction. The private placement is expected to close on or prior to October 29, 2026. The Company currently expects to use the net proceeds from the private placement to fund Phase 3 preparatory activities for Halneuron® and for working capital and general corporate purposes.